BioPharma Dive November 15, 2024
At an event hosted by BioPharma Dive, drugmaker executives and investors offered advice for how startups can navigate the current market.
Market downturns take a toll. For many young biotechnology companies, the past few years have been a lesson in survival, as the evaporation of the sector’s pandemic-era boom brought cutbacks to the investment they so desperately need.
“Platform” companies, so called for their focus on broad drugmaking technologies rather than one or two specific medicines, felt this shakeout acutely. Once in vogue, they now seem to be somewhat out of favor among venture capitalists, who are looking to product-focused startups as safer bets.
“I think it is unequivocal that there has been a shift,” David Yang, an investor at...
Today's Sponsors
Today's Sponsor